PCSK9 Inhibitors: What Do Cardiologists Think?
This article was originally published in Scrip
Executive Summary
Cardiologists appear confident of both the efficacy and safety of the new PCSK9 inhibitors, even ahead of their cardiovascular outcomes trial (CVOT) data, a new survey by BioMedTracker has found.